In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Health And Wellness Industry Regulatory And Litigation News

This article is powered by The Rose Sheet

Executive Summary

FTC ends 9-party supplement claims enforcement with three last settlements; ginkgo class action against Nature’s Bounty dismissed; and litigation dismissed when suspect sexual enhancement supplements removed from website.

You may also be interested in...



Gingko Supplement Adulteration Points To Broader Problem For FDA – CSPI

Nutrition and food safety watchdog group asks FDA to enforce against marketers of ginkgo supplements after ConsumerLab.com found that six of 10 ginkgo supplements it tested contained either less of the herb than advertised or different and cheaper plant material.

NDI Notification Costs Estimate, P&G Board: Health And Wellness Industry News

FDA NDI notification costs estimate unchanged; P&G proxy vote update favors Peltz; and trio of advertising violations for California supplement, skin care firms.

XXL Impressions Supplement Memory Claims Impress FTC As False

FTC announces agreements to settle complaints against six of nine defendants identified in an investigation of XXL Impressions' advertising for CogniPrin promoted for cognitive benefits and FlexiPrin product promoted to reduce joint paint and rebuild damaged joints and cartilage.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS121161

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel